cord.
8 It is believed that auto immuno logic phe nomena similar to those present in other organs involved in SLE are responsible for development of vascular lesions in the spinal cord.
7 Lack of more recent pathomorpho logical data is proba bly a result of a more favorable clinical course of the disease associated with intensive immuno suppressive therapy.
Myelopathy in patients with systemic lupus erythematosus Involvement of the nervous system is common in patients with SLE. Depending on the accepted criteria it is estimated that symptoms of nervous system involvement are present in ap proximately 25-80% of patients. 9, 10 In 1999 the Research Committee of the Amer ican College of Rheumatology (ACR) defined 19 neuropsychiatric syndromes that may occur in the course of SLE and determined precise criteria of their diagnosis. 10, 11 The most common neuropsy chiatric forms of SLE include: headaches, cerebro vascular disease, mood changes, cognitive disor ders and convulsions. 9 Myelopathy is one of the less common neu ropsychiatric manifestations of SLE (1-3% of pa tients). 4, 9, 12, 13 Diagnostic criteria for myelopa thy in SLE according to the ACR are presented in TABLE 2. The most common form is ATM. Longitu dinal myelitis is less frequently observed. 14 Until recently, it has been believed that in flammatory lesions in the course of myelopathy in patients with SLE involve a relatively short, 1 to 4segmentlong section of the spinal cord.
15
All cases of myelitis were referred to as ATM. a connective tissue disease constitute one of the exclusion criteria for idiopathic ATM.
Among systemic connective tissue diseases, ATM is most commonly encountered in system ic lupus erythematosus (SLE), less frequently in antiphospholipid syndrome (APS) or secondary antiphospholipid syndrome (SAPS). 6 ATM was only sporadically reported in the course of oth er connective tissue diseases, including Sjögren's syndrome, Behçet's disease, mixed connective tis sue disease.
1,2
Pathomechanism A precise mechanism of in flammatory lesion formation in the spinal cord of patients with SLE has not yet been discovered. Based on papers published in the 1970s it is sug gested that vasculitis and arterial thrombi lead ing to spinal cord ischemic necrosis, are respon sible for patho logical lesions.
7 Autopsy showed various vascular changes within the spinal cord in 11 out of 12 individuals who died because of ATM. The abnormalities included ischemic ne crosis, infarction or malacia in 8 cases, vascu litis without necrotic foci in 2 cases and degen erative lesions within the white matter with ad ventitia thickening in small arteries in 1 patient. Vascular patho logies involved perivascular lym phocytic infiltrations, proliferation of connective tissue, thrombi in small vessels (small arteries and arterioles), microextravasations within the spinal cord parenchyma.
7 Autopsy performed by other authors in one patient showed perivascu lar cellular infiltrations, presence of inflamma tory cells and colliquative necrosis of the spinal An episode of acute myelitis may be preceded by general symptoms, including fever, malasia, dizziness, photophobia, nausea, vomiting, neck pain, back or girdle pain of the trunk. 6, 8 In cases of patients with accompanying cerebrospinal menin gitis nuchal rigidity was also observed. 20, 21 Usually a short period of nonspecific pro dromal symptoms is followed by bilateral lower limb paresthesia with accompanying sensation of numbness and reduction of muscular power, quickly evolving into a complete or partial para plegia, or less frequently tetraplegia, with accom panying sensory impairment, retention of urine and fecal incontinence. 7, 8 Motor dysfunction is always bilateral but not necessarily symmetrical. The level of motor dys function may be different, ranging from a com plete para lysis, various levels of paresis, to a minor reduction in muscular power manifested by some difficulties with standing and walking. 13 During the initial period para lysis of limbs is a flaccid para lysis with abolition of deep reflexes and reduced muscular tonus. Spastic para lysis de velops in several days or weeks. Sometimes, flac cid para lysis persists. 3, 5 Myelitis may be ascending. Initially paresis/ paralysis involves only lower limbs and gradual ly covers also upper limbs and finally it may lead to para lysis of respiratory muscles with resulting respiratory failure.
7,21 The level of inflammatory changes occurrence in the spinal cord and extent of the inflammatory process are factors deciding on the scope of motor dysfunction and the level of sensory impairment.
The area of sensory impairment is usually clear ly limited.
3 Similarly to motor dysfunction, senso ry impairment may be of various intensity, from a total lack of sensitivity below the level corre sponding to the spinal cord damage, to a selec tive analgesia and thermesthesia with preserved deep and vibratory sensibility.
24 Sensory impair ment is commonly found in the thoracic section of the trunk, which is explained by poor vascu larization of the corresponding section of the spinal cord. Currently, possibly due to improvement in qual ity and availability of magnetic resonance imag ing (MR), an increasing number of diagnoses of the socalled longitudinal myelitis is noted. The condition is associated with inflammatory chang es involving spinal cord sections of more than 4segment length, usually several segments or even the whole length of the spinal cord. Inflam matory changes are not always continuous. Some times they are present in 2 separate localizations at some distance from each other. 14, 16, 17 The term ATM is still used by several authors to describe all cases of myelitis, regardless of the length of the spinal cord occupied by inflamma tion. 1,2,5 Use of the term is justified because, re gardless of the number of spinal cord segments involved by inflammation, always the same clin ical presentation is observed -transverse spinal cord damage. Recently a report has been pub lished. It recommends that all cases of myelitis -both transverse and longitudinal -in patients with SLE be referred to as lupus myelopathy. 18 In patients with myelitis in SLE, symptoms of acute spinal cord damage are usually accompanied by other neuro logical manifestations of SLE, most commonly by optic neuritis. Other less common symptoms include depression, dysmnesia, con vulsions, psychosis, ophthalmoplegia. 4, 13, 19 There are also reports of single ATM cases preceded by aseptic cerebrospinal meningitis. [19] [20] [21] ATM with associated optic neuritis is referred to as Devic's syndrome in literature and currently recognized as a separate disease belonging to de myelinating diseases.
22 Coexistence of optic neu ritis and ATM has been found in 21-48% of pa tients with myelopathy in SLE.
4,18
In the majority of cases, myelitis occurs shortly after SLE is diagnosed, usually within the first 5 years from the onset of the disease. 4, 13 In nearly half of patients ATM is the first clinical manifes tation of SLE. 4 The disease usually affects young and middleaged females, although some males might be affected. 4, 13 Recurrence of myelitis within several months after the first episode of myelopathy is relatively frequently observed in patients with ATM in SLE. At least one recurrence of ATM in SLE is noted in 21-55% of patients. 4, 13, 23 Episodes of recurrence were found mainly in untreated patients and in patients receiving longterm therapy with low or medium doses of glucocorticosteroids. According to some investigators, analysis of the cerebrospinal fluid does not show any altera tions. 13, 27, 28 Other authors, including the authors of this report, claim that pleocytosis with prev alence of granulocytes, increased protein levels, low glucose and positive protein reactions are observed in cerebrospinal fluid (CSF) of patients with ATM in SLE. 17, 18, 21, 24 A number of cells may be variable and may sometimes exceed a thousand in a microliter, glucose levels may be reduced to several milligrams per deciliter. It is suggested that a low glucose level in CSF is present on the first days of the disease, and then it returns to normal. 7 It should be noted that low CSF glucose levels are not observed in other neuro logical man ifestations of SLE, or in idiopathic ATM.
13

24
In the light of scarce observations made by the authors of this report (2 cases) which have not been confirmed by others yet, antibodies charac teristic of SLE may be found in CSF of patients with acute ATM in SLE. 21 Only a few similar ob servations have been published and they con firmed the presence of antibodies in CSF of pa tients with other neuro logical manifestations in the course of SLE.
29,30 However, results reported by other authors do not support this concept.
31,32
A suggested mechanism responsible for presence of antibodies in CSF involves intrathecal synthe sis of immunoglobulins in patients with SLE in volving the central nervous system. 30 differential diagnosis Transverse myelitis should be differentiated from spinal cord transverse damage resulting from compression by various patho logical structures, for example tumor mass es, inflammatory granulation tissue of bacterial etiology, vascular malformations, and second ary changes to a previous injury or spinal cord radiotherapy.
A possible concurrent neural infection in the course of viral, bacterial or para sitic infection must be considered in patients with fever who have abnormal CSF test results. Careful history taking and analysis of the whole clinical presenta tion is necessary, because patients with diagnosed SLE usually receive immunosuppressive agents, Autonomous nervous system dysfunction is observed in all patients with ATM. Initial symp toms include urine retention with overfilling of the urinary bladder and para lysis of intestinal peristalsis with retention of gases and feces. Sev eral days later, in the next stage, urinary inconti nence develops, intestinal peristalsis returns but fecal incontinence persists. Neurogenic bladder is gradually developed. 13 Moreover, vasomotor dys functions and perspiration disorders appear be low the border of the region of sensory impair ment, followed by trophic changes in para lysed limbs. Limbs become cool and livid. Distal ede ma may appear. 3
Imaging The imaging technique of choice in cas es of suspected ATM is MR with intravenous con trast agent (gadolinium diethylenetriaminepen taacid). The imaging should cover at least the area corresponding to the level of damage evaluated based on a neuro logical examination. It has been recently recommended that the whole length of the spinal cord be included in the image. MR of the brain is also recommended in patients with di agnosed myelitis in order to exclude the presence of demyelinization foci. The recommendation is particularly valid for patients with the inflamma tory process confirmed by lumbar puncture. 1 Inflammatory changes in the spinal cord are visible in T 2 weighted MR images as intensifica tion of a signal from the central part of the spinal cord and as an edema increasing the spinal cord thickness by several millimeters. In the majority of patients intensification of signal in T 2 weight ed images becomes more pronounced following administration of the contrast agent. 1, 15, 25, 26 It should be noted that as much as 30% of patients with diagnosed ATM in SLE presented normal im age of the spinal cord in MR.
4 If initial MR does not reveal any inflammatory changes within the spinal cord intensifying after introduction of the contrast medium it is recommended to repeat MR 2-7 days after the onset of the disease.
1
The reduction in inflammatory lessions visible in MR is observed in successfully treated patients. On the other hand, MR of patients in whom in flammatory lesions sustained may show atrophy within the spinal cord.
8
It has recently been agreed that computed to mography (CT) is not sufficiently sensitive to be a rationale for the diagnosis of myelitis. There fore the technique is not recommended in pa tients with symptoms of transverse spinal cord damage. Use of CT should be only considered if MR is unavailable and in order to exclude com pression of the spinal cord.
1
Laboratory tests An increasing erythrocyte sed imentation rate from a low to a threedigit val ue, increased Creactive protein values and a re duction in complement constituent levels are ob served in the majority of patients in the acute stage of the disease.
4,13,14,21 Other alterations of laboratory test results may also be present in hypothesis that inflammatory lesions in the spi nal cord are a result of thrombosis in the medul lary vessels. 4,7 Addition of antithrombotic ther apy is especially recommended in patients with APA antibodies present in serum. 6 Single reports on positive effects of therapy with rituximab (antiCD20 receptor antibody) 34 and of auto logous bone marrow transplantation 23 have been published recently. After 2 infusions with rituximab given to a patient with contrain dications to therapy with cyclophosphamide and uneffective glucocorticosteroid therapy, a distinct and rapid improvement in neuro logical condition was observed. 34 Autologous bone marrow trans plantation was performed in a patient with recur ring severe neuro logical symptoms in the course of SLE that persisted despite therapy with cyclo phosphamide and glucocorticosteroids, which re sulted in remission of SLErelated symptoms and a reduction in paresis.
23
Single reports have also been published on suc cessful intrathecal therapy with dexamethasone and methotrexate. In some patients this intrath ecal administration of immunosuppressants has been repeated several times. 18, 35, 36 Symptomatic treatment is also of importance in therapy of patients with ATM. Foley catheter insertion to the urinary bladder is necessary in the early stage of the disease, when urinary re tention occurs, because overflow of the bladder caused by sphincter para lysis may lead to rup ture. 3 Intensive antibedsore care is needed. Pa tients with spinal para lysis easily develop bed sores due to immobility, sensory impairment and damaged auto nomic nervous system. 13, 21 Patients with ATM also require a complex and intensive rehabilitation which should be started already in the first days of the disease. 13
Prognosis Data on longterm prognosis of the disease are conflicting. Complete recovery, par tial remissions, arrest of progress of the disease, and deterioration of neuro logical symptoms, in cluding death of a patient might occur.
It has recently been agreed that early intro duction of immunosuppressive therapy with in travenous cyclophosphamide and high doses of glucocorticosteroids, followed by oral glucocor ticosteroids improves the longterm prognosis of patients with ATM in SLE. 4, 8, 24, 28 The earlier im munosuppressive therapy is introduced and the more aggressive it is, the better the longterm prognosis is.
6,18 Considering lack of sufficiently large sample sizes of patients with myelopathy there are no unanimous results of studies on ef fectiveness of ATM therapy based on reliable re sults of clinical tests. 14 Prognosis in patients with MR alterations is poor compared to those patients with no such ab normalities.
4 Prognosis is particularly poor in pa tients with extensive spinal lesions involving the whole length of the spinal cord. 16 Patients with inflammatory lesions visible in the MR of the spi nal cord that resolve after the first, preliminary and are at higher risk of coexisting infection. Un fortunately, results of CSF general tests and sed iment test may be identical in patients with my elitis in SLE and patients with neural infection in the course of bacterial infections (pleocytosis, high protein levels, low glucose levels). Therefore, an adequate culture is necessary to exclude a pos sible infection. This may delay the appropriate im munosuppression therapy. Clinical observations made by the authors of this report suggest that the presence of SLEassociated antibodies in CSF favors the diagnosis of ATM in SLE. 21 Differential diagnosis should also consider scle rosis multiplex. An earlier clinically evident demy elinization episode in history, MR of the spinal cord and the brain suggesting multiple sclerosis (demyelinization changes disseminated in space and time occupying not more than 2 segments of the spinal cord and less than 50% of its diameter) and presence of bands of oligoclonal antibodies in the CSF test indicate the disease. 1, 5, 33 Moreover, ATM should be differentiated from Devic's syndrome currently most frequently re ferred to as neuromyelitis optica (NMO). It is an idiopathic demyelininating disease involving recurrent episodes of optic neuritis and trans verse myelitis. Precise criteria for the diagno sis of this disease have been recently developed based on a modern, highly sensitive and specific NMOIgG antibody. 22, 33 Aquaporin 4 -a protein forming one of the main water channels within the central nervous system -is a target antigen for NMOIgG. 22 Idiopathic myelitis should be diagnosed in pa tients who do not meet diagnostic criteria for SLE and in whom no symptoms suggestive of anoth er disease are observed.
Therapy Because of low prevalence of myelitis there are no precise and unanimous recommen dations for standard therapy of ATM in SLE.
Currently, use of glucocorticosteroids and cy clophosphamide is a standard therapy of SLE in volving the central nervous system, including myelopathy in SLE.
6 It is postulated that ther apy of patients with SLE and ATM symptoms should be started with intravenous 1 g methyl prednisolone for 3 days, followed by cyclophos phamide (1 g/m2 of body surface area), and con tinued with oral glucocorticosteroids. In more se vere cases additional plasmapheresis for 5 days with complete plasma exchange is recommend ed. However, there is no unanimous evidence of effectiveness of this therapy.
4 Some authors pos tulate repeated cycles of immunosuppression in therapyresistant cases.
28 However, duration and frequency of the repeated cycles have not been determined. Sole infusions of glucocorticoster oids were effective in some cases of ATM.
4 In se vere cases some authors additionally used intra venous immunoglobulins. 23, 34 There are controversies as to whether anti thrombotic therapy is appropriate. Some authors postulate the need of this therapy based on the 24 Propper DJ, Bucknall RC. Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis. 1989; 48: 512-515. 25 Boumpas DT, Patronas NJ, Dalakas MC, et al. Acute transverse myelitis in systemic lupus erythematosus: magnetic resonance imaging and review of the literature. J Rheumatol. 1990; 17: 89-92 . There is also poor prognosis in patients with a dramatic clinical course of myelitis, encountering the socalled, medullary shock phase and whose initially evaluated deficit in muscular power is very large. 8, 18, 19 An association between the ini tial high SLE activity and the longterm progno sis has not been confirmed. 4, 18 The time of complete or partial improvement in neuro logical function may be variable, ranging between several days and many months. 5, 7, 34 REfEREnCEs
